Author:
Balfoort Berith M.,Van Den Broeck Filip,Brands Marion M.,van Karnebeek Clara D.,Bergen Arthur A.,van den Born L. Ingeborgh,Houtkooper Riekelt H.,Wagenmakers Margreet A. E. M.,De Zaeytijd Julie,Leroy Bart P.,Boon Camiel J. F.,Diederen Roselie M. H.
Abstract
Abstract
Purpose
Gyrate atrophy of the choroid and retina (GACR) is an autosomal recessive inherited metabolic disorder (IMD) characterised by progressive retinal degeneration, leading to severe visual impairment. The rapid developments in ophthalmic genetic therapies warrant knowledge on clinical phenotype of eligible diseases such as GACR to define future therapeutic parameters in clinical trials.
Methods
Retrospective chart analysis was performed in nineteen patients. Data were analysed using IBM SPSS Statistics version 28.0.1.1.
Results
Nineteen patients were included with a mean age of 32.6 years (range 8–58). Mean age at onset of ophthalmic symptoms was 7.9 years (range 3–16). Median logMAR of visual acuity at inclusion was 0.26 (range -0.18–3.00). Mean age at cataract surgery was 28.8 years (n = 11 patients). Mean spherical equivalent of the refractive error was -8.96 (range -20.87 to -2.25). Cystoid maculopathy was present in 68% of patients, with a loss of integrity of the foveal ellipsoid zone (EZ) in 24/38 eyes. Of the 14 patients treated with dietary protein restriction, the four patients who started the diet before age 10 showed most benefit.
Conclusion
This study demonstrates the severe ophthalmic disease course associated with GACR, as well as possible benefit of early dietary treatment. In addition to visual loss, patients experience severe myopia, early-onset cataract, and CME. There is a loss of foveal EZ integrity at a young age, emphasising the need for early diagnosis enabling current and future therapeutic interventions.
Funder
Stichting Metakids
Amsterdam Gastroenterology Endocrinology and Metabolism
Publisher
Springer Science and Business Media LLC